

Periinterventionelles Management direkter oraler Antikoagulanzen (DOAKs)

1. Harbrecht, U., Old and new anticoagulants. *Hamostaseologie*, 2011. 31(1): p. 21-7.
2. Douketis, J.D., et al., The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, 2008. 133(6 Suppl): p. 299-339.
3. Eisele, R., N. Melzer, and P. Bramlage, Perioperative management of anticoagulation. *Chirurg*, 2014. 85(6): p. 513-9.
4. Giebl, A. and K. Gurtler, New oral anticoagulants in perioperative medicine. *Anaesthesist*, 2014. 63(4): p. 347-62.
5. Lee, L.H., DOACs - advances and limitations in real world. *Thrombosis Journal*, 2016. 14(Suppl 1): p. 134-163.
6. van Es, N., et al., Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. *Blood*, 2014. 124(12): p. 1968-75.
7. Tummala, R., et al., Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data. *Int J Cardiol*, 2016. 214: p. 292-8.
8. Siegal, D.M. and M.A. Crowther, Acute management of bleeding in patients on novel oral anticoagulants. *Eur Heart J*, 2013. 34(7): p. 489-498b.
9. Waurick, K., et al., 3. überarbeitete Empfehlung der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin: S1-Leitlinie „Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/antithrombotische Medikation“. *Anästhesiologie & Intensivmedizin*, 2014. 55: p. 464-492.
10. Hart, C. and M. Spannagl, Gerinnungsmonitoring der direkten oralen Antikoagulanzen. *Kardiologie up2date*, 2013. 9: p. 197-211.
11. Samos, M., et al., Monitoring of dabigatran therapy using Hemoclot((R)) Thrombin Inhibitor assay in patients with atrial fibrillation. *J Thromb Thrombolysis*, 2015. 39(1): p. 95-100.
12. Grottke, O. and J.H. Levy, Prothrombin complex concentrates in trauma and perioperative bleeding. *Anesthesiology*, 2015. 122(4): p. 923-31.
13. Siegal, D.M. and A. Cuker, Reversal of novel oral anticoagulants in patients with major bleeding. *J Thromb Thrombolysis*, 2013. 35(3): p. 391-8.
14. Finks, S.W. and K.C. Rogers, Idarucizumab (Praxbind(R)): The first reversal agent for a direct oral anticoagulant. *The American Journal of Medicine*, 2016.